MAS825F
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $2.7M | 22 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2.7M | 22 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED, PARTICIPANT AND INVESTIGATOR BLINDED, MULTI-CENTER STUDY TO ASSESS EFFICACY AND SAFETY OF MAS825 FOR THE TREATMENT OF SARS-COV-2 INFECTED PATIENTS WITH COVID-19 PNEUMONIA AND IMPAIRED RESPIRATORY FUNCTION | Novartis Pharmaceuticals Corporation | $2.7M | 0 |
| A PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED, PARTICIPANT AND INVESTIGATOR BLINDED, MULTI-CENTER STUDY TO ASSESS EFFICACY AND SAFETY OF MAS825 FOR THE TREATMENT OF SARS-COV-2 INFECTED PATIENTS WITH COVID-19 PNEUMONIA AND IMPAIRED RESPIRATORY FUNCTION | NOVARTIS PHARMACEUTICALS CORPORATION | $8,000 | 0 |
Top Doctors Receiving Payments for MAS825F
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Asheville, NC | $2.7M | 22 |
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $2.7M
- Total Doctors 0
- Transactions 22
About MAS825F
MAS825F is a drug associated with $2.7M in payments to 0 healthcare providers, recorded across 22 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2020 to 2020. In 2020, $2.7M was paid across 22 transactions to 0 doctors.
The most common payment nature for MAS825F is "Unspecified" ($2.7M, 100.0% of total).
MAS825F is associated with 2 research studies, including "A PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED, PARTICIPANT AND INVESTIGATOR BLINDED, MULTI-CENTER STUDY TO ASSESS EFFICACY AND SAFETY OF MAS825 FOR THE TREATMENT OF SARS-COV-2 INFECTED PATIENTS WITH COVID-19 PNEUMONIA AND IMPAIRED RESPIRATORY FUNCTION" ($2.7M).